Advisory Committee on Immunization Practices, 66451-66452 [2023-20949]

Download as PDF Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices information about the Committee, including meeting materials and agendas, will be made available on-line at https://www.gsa.gov/gbac. SUPPLEMENTARY INFORMATION: • Working Lunch with Speaker • Discussion of Next Potential Committee Topics • Public Comments • Adjourn Procedures for Attendance and Public Comment To register to attend the November 2nd meeting as a public observer, please send the following information via email to gbac@gsa.gov: your first and last name, organization and email address and whether you would like to provide public comment. Requests to observe the November 2nd, 2023 meeting must be received by 12 p.m. ET, on Monday, October 30, 2023 to receive the meeting information. Requests to observe the full series of Task Group meetings must be received by 5 p.m. ET on the Monday before the meeting in question. Since Task Group meetings are conducted as a series, it will be most useful to observe all or most of them from the start. For all online meetings, Web meeting attendance information will be provided following registration. Time will be provided at all meetings for public comment wherever possible. GSA will be unable to provide technical assistance to any listener experiencing technical difficulties. Testing access to the Web meeting site before the calls is recommended. To request an accommodation, such as closed captioning, or to ask about accessibility, please contact Mr. Bloom at gbac@gsa.gov at least five business days prior to the meeting to give GSA as much time as possible to process the request. Green Building Advisory Committee ddrumheller on DSK120RN23PROD with NOTICES1 Background The Administrator of GSA established the Committee on June 20, 2011 (Federal Register/Vol. 76, No. 118) pursuant to Section 494 of the Energy Independence and Security Act of 2007 (EISA, 42 U.S.C. 17123). Under this authority, the Committee provides independent policy advice and recommendations to GSA to advance federal building innovations in planning, design, and operations to reduce costs, enable agency missions, enhance human health and performance, and minimize environmental impacts. November 2nd Meeting Agenda • Welcome • Introductions • Task Group Presentations, Recommendations and Vote (as needed) Æ Federal Building Decarbonization Æ Green Leasing VerDate Sep<11>2014 18:44 Sep 26, 2023 Jkt 259001 Federal Building Decarbonization Task Group The Federal Building Decarbonization Task Group will work to develop recommendations to the full Committee to propose to GSA, to prioritize federal building decarbonization strategies. This phase of the Task Group builds on the findings of the first two phases of this Task Group with a deeper investigation of issues related to beneficial federal building electrification. Kevin Kampschroer, Federal Director, Office of Federal HighPerformance Green Buildings, General Services Administration. [FR Doc. 2023–20967 Filed 9–26–23; 8:45 am] BILLING CODE 6820–14–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2023–0079] Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on October 25, 2023, from 8 a.m. to 5 p.m., EDT, October 26, 2023, from 8 a.m. to 5 p.m., EDT, and October 27, 2023, from 8 a.m. to 12 p.m., EDT (times subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/ acip/). Written comments must be received between October 2–13, 2023. ADDRESSES: You may submit comments, identified by Docket No. CDC–2023– 0079, by either of the methods listed below. CDC does not accept comments by email. SUMMARY: PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 66451 • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2023–0079. Instructions: All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/ index.html. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussions on child and adolescent immunization schedules, adult immunization schedule, influenza vaccines, chikungunya vaccine, COVID– 19 vaccines, meningococcal vaccines, mpox vaccine, pneumococcal vaccines, polio vaccines, and respiratory syncytial E:\FR\FM\27SEN1.SGM 27SEN1 66452 Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices ddrumheller on DSK120RN23PROD with NOTICES1 virus vaccines for older adults. Recommendation votes on child and adolescent immunization schedules, adult immunization schedule, meningococcal vaccines, and mpox vaccine are scheduled. A Vaccines for Children vote on meningococcal vaccines and mpox vaccine is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/ meetings/. Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on October 2, 2023. Written comments must be received by October 13, 2023. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the October 25–27, 2023, ACIP meeting must submit a request at https://www.cdc.gov/ VerDate Sep<11>2014 18:44 Sep 26, 2023 Jkt 259001 vaccines/acip/meetings/ between October 2, 2023, and no later than 11:59 p.m., EDT, October 13, 2023, according to the instructions provided. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by October 17, 2023. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may speak only once per meeting. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2023–20949 Filed 9–26–23; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier: CMS–2540–23 and CMS–10448] Agency Information Collection Activities: Proposed Collection; Comment Request Centers for Medicare & Medicaid Services, Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the SUMMARY: PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. DATES: Comments must be received by November 27, 2023. ADDRESSES: When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways: 1. Electronically. You may send your comments electronically to https:// www.regulations.gov. Follow the instructions for ‘‘Comment or Submission’’ or ‘‘More Search Options’’ to find the information collection document(s) that are accepting comments. 2. By regular mail. You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number: ll, Room C4–26–05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, please access the CMS PRA website by copying and pasting the following web address into your web browser: https://www.cms.gov/ Regulations-and-Guidance/Legislation/ PaperworkReductionActof1995/PRAListing. FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786–4669. SUPPLEMENTARY INFORMATION: Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection’s supporting statement and associated materials (see ADDRESSES). CMS–2540–23—Skilled Nursing Facility and Skilled Nursing Facility Healthcare Complex Report CMS–10448—Essential Health Benefits Benchmark Plans Under the PRA (44 U.S.C. 3501– 3520), federal agencies must obtain E:\FR\FM\27SEN1.SGM 27SEN1

Agencies

[Federal Register Volume 88, Number 186 (Wednesday, September 27, 2023)]
[Notices]
[Pages 66451-66452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20949]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2023-0079]


Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee on Immunization Practices (ACIP). This meeting 
is open to the public. Time will be available for public comment.

DATES: The meeting will be held on October 25, 2023, from 8 a.m. to 5 
p.m., EDT, October 26, 2023, from 8 a.m. to 5 p.m., EDT, and October 
27, 2023, from 8 a.m. to 12 p.m., EDT (times subject to change; see the 
ACIP website for updates: https://www.cdc.gov/vaccines/acip/).
    Written comments must be received between October 2-13, 2023.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0079, by either of the methods listed below. CDC does not accept 
comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2023-0079.
    Instructions: All submissions received must include the Agency name 
and docket number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.
    The meeting will be webcast live via the World Wide Web. The 
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management 
Specialist, Advisory Committee on Immunization Practices, National 
Center for Immunization and Respiratory Diseases, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, 
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].

SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on 
Immunization Practices (ACIP) is charged with advising the Director, 
Centers for Disease Control and Prevention (CDC), on the use of 
immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is 
mandated to establish and periodically review and, as appropriate, 
revise the list of vaccines for administration to vaccine-eligible 
children through the Vaccines for Children program, along with 
schedules regarding dosing interval, dosage, and contraindications to 
administration of vaccines. Further, under applicable provisions of the 
Affordable Care Act and section 2713 of the Public Health Service Act, 
immunization recommendations of ACIP that have been approved by the 
Director, CDC, and appear on CDC immunization schedules generally must 
be covered by applicable health plans.
    Matters To Be Considered: The agenda will include discussions on 
child and adolescent immunization schedules, adult immunization 
schedule, influenza vaccines, chikungunya vaccine, COVID-19 vaccines, 
meningococcal vaccines, mpox vaccine, pneumococcal vaccines, polio 
vaccines, and respiratory syncytial

[[Page 66452]]

virus vaccines for older adults. Recommendation votes on child and 
adolescent immunization schedules, adult immunization schedule, 
meningococcal vaccines, and mpox vaccine are scheduled. A Vaccines for 
Children vote on meningococcal vaccines and mpox vaccine is scheduled. 
Agenda items are subject to change as priorities dictate. For more 
information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web. For more information on ACIP, please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near-duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on October 2, 2023. Written comments must be received 
by October 13, 2023.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Oral public comment will occur 
before any scheduled votes, including all votes relevant to the ACIP's 
Affordable Care Act and Vaccines for Children Program roles. Priority 
will be given to individuals who submit a request to make an oral 
public comment before the meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the October 25-27, 2023, ACIP meeting must 
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ between October 2, 2023, and no later than 11:59 p.m., EDT, 
October 13, 2023, according to the instructions provided.
    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email by October 17, 2023. To accommodate the significant 
interest in participation in the oral public comment session of ACIP 
meetings, each speaker will be limited to three minutes, and each 
speaker may speak only once per meeting.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-20949 Filed 9-26-23; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.